HopeStage
Back to all studies
RecruitingEUCTR 2022-000054-28

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

This historical record does not confirm current site availability.

Historical research recordGermany
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Listed locations
Augsburg and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Klinikum der Universität München
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Germany
Age range
Not clearly listed
Official registry ID
EUCTR 2022-000054-28
Official title
Show the full official title

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Recruitment & locations

Currently recruiting

Augsburg · Munich

Registry detailsOriginal registry record (opens in a new tab)
Current country statuses
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Klinikum der Universität München.

Who can participate?

This study is for people with schizophrenia. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies